EHA 2022 | The safety and efficacy of KER-050 for the treatment of patients with lower-risk MDS
Shuh Ying Tan
• 29 Jun 2022
Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, discusses the safety and tolerability of KER-050 for the treatment of patients with lower-risk myelodysplastic syndromes (MDS). Dr Tan first highlights the mechanism of action of KER-050, and then goes on to discuss the preliminary results from this Phase II study, which indicated that this agent was well tolerated and demonstrated high efficacy in patients with lower-risk MDS. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
